Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma

European Respiratory Journal

Volumn 21, Issue 6, 2003, Pages 1046-1049

  Babu, K S ^a   Woodcock, D A ^b   Smith, S E ^a   Staniforth, J N ^c   Holgate, S T ^a   Conway, J H ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b Britannia Pharmaceuticals Limited   (United Kingdom)

^c University of Bath   (United Kingdom)

Author keywords

Allergen provocation; Asthma; Asthmatic surfactant; Pumactant

Indexed keywords

ALLERGEN; ARTIFICIAL LUNG SURFACTANT; LUNG SURFACTANT; PHOSPHOLIPID;

ADULT; AIRWAY; ALLERGIC ASTHMA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; DRY POWDER; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; INHALATION TEST; LUNG EDEMA; PRIORITY JOURNAL; PROVOCATION TEST; PUSTULE; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY; VIRUS INFECTION;

EID: 0038652086     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00069202     Document Type: Article

References (13)

1. Hohlfeld JM. The role of surfactant in asthma. Respir Res 2001; 3: 4-12.
2. Kurashima K, Ogawa H, Ohka T, Matsuda T, Kobayashi T. A pilot study of surfactant inhalation in the treatment of asthmatic attacks. Arerugi 1991; 40: 160-163.
3. Heeley EL, Hohlfeld JM, Krug N, Postle AD. Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma. Am J Physiol Lung Cell Mol Physiol 2000; 278: L305-L311.
4. Wright SM, Hockey PM, Enhorning G, et al. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol 2000; 89: 1283-1292.
5. Hills BA, Chen Y. Suppression of neural activity of bronchial irritant receptors by surface-active phospholipid in comparison with topical drugs commonly prescribed for asthma. Clin Exp Allergy 2000; 30: 1266-1274.
6. Chai H, Farr RS, Froehlich LA, et al. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975; 56: 323-327.
7. Hohlfeld JM, Ahlf K, Enhorning G, et al Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am J Respir Crit Care Med 1999; 159: 1803-1809.
8. Hills BA. Asthma: is there an airway receptor barrier? Thorax 1996; 51: 773-776.
9. Wilsher ML, Parker DJ, Haslam PL. Immunosuppression by pulmonary surfactant: mechanisms of action. Thorax 1990; 45: 3-8.
10. Becher G. Lung surfactant prevents allergic bronchial constriction in ovalbumin sensitized guinea pigs. Biomed Biochim Acta 1985; 44: K57-K61.
11. Richman PS, Batcher S, Catanzaro A. Pulmonary surfactant Suppresses the immune lung injury response to inhaled antigen in guinea pigs. J Lab Clin Med 1990; 116: 18-26.
12. Oetomo SB, Dorrepaal C, Bos H, et al Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am J Respir Crit Care Med 1996; 153: 1148-1152.
13. Hills BA. An alternative view of the role(s) of surfactant and the alveolar model. J Appl Physiol 1999; 87: 1567-1583.